原发性肝癌的综合介入治疗及其根治性疗效分析

目的 探讨原发性肝癌的综合介入治疗及其根治性的疗效.方法 回顾性分析2003年1月至2008年1月间本院接受住院综合介入治疗的538例原发性肝癌患者的临床资料和治疗方案.分析原发性肝癌的综合介入治疗及其根治性疗效.结果 20例(3.7%,20/538)首次评价中出现"进展",余518例曾获得过"有效"评价结果 ;其中416例(77.3%,416/538)最终出现"进展"评价结果 ,进展最快出现在首次治疗后4月,最慢出现在首次治疗后24月;102例(19.0%,102/538)则获得"显效"评价结果 ,其中53例最后获得"根治"评价结果 .这53例患者目前全部存活,随访时间最长为64个月,最短为16个月,中位生存期为36.5个月.结论 综合介入治疗是原发性肝癌的有效治疗手段,可使部分原发性肝癌患者获得根治.

Radical efficacy evaluation of comprehensive interventionai therapy for primary hepatocellular carcinoma

Objective To explore the clinical value of interventional invasive therapy in primary hepatocellular carcinoma (PHCC) and it' s radical efficacy. Methods The retrospective analysis was undertaken in 538 patients between January 2003 and January 2008 in our hospital with PHCC. The treatment and the radical efficacy were evaluated. Results Twenty patients(3.7%, 20/538) get progression after the first treatment, 518 patients (518/538) had ever gained effective cure, of whom progression occurred in 416 patients (77.3%, 416/538)at last. The earliest progression occurred 4 months after the first therapy, and the latest occurred 24 months later. One hundred and two (19.0%, 102/538) patients gained evident effective cure, 53 of whom gained radical cure, and they are still alive. The longest follow-up time was 64 months, the shortest was 16 months, and the median survival span estimation in the recent follow-up was 36.5 months. Conclusion Comprehensive interventional therapy is an effective and safe therapy for PHCC, and some patients can gain radical cure.